2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-139801
    Indolapril hydrochloride 80828-32-6 98%
    Indolapril hydrochloride (CI-907) is an orally active nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor. Indolapril hydrochloride is highly specific in suppressing the contractile or pressor responses to Angiotensin I. Indolapril hydrochloride is a potent antihypertensive agent.
    Indolapril hydrochloride
  • HY-139803
    SCH-39370 115406-23-0 98%
    SCH-39370 is a potent and specific inhibitor of neutral metalloendopeptidase (NEP) from rabbit kidney with an IC50 value of 11.2 nM. SCH-39370 potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats.
    SCH-39370
  • HY-139876
    APJ receptor agonist 3 2759159-56-1 98%
    APJ receptor agonist 3 is a potent and orally active APJ receptor agonist with an EC50 value of 0.027 nM.
    APJ receptor agonist 3
  • HY-139993
    HIF-PHD-IN-2 2711720-45-3 98%
    HIF-PHD-IN-2 (compound 25) is a potent PHD inhibitor with IC50s of <100 nM for PHD1, PHD2 and PHD3, respectively.
    HIF-PHD-IN-2
  • HY-141469
    6,9,12,15,18-Heneicosapentaenoic acid 65919-53-1 98%
    6,9,12,15,18-Heneicosapentaenoic acid (HPA; Heneicosapentaenoic acid methyl ester) inhibits the conversion of α-linoleic acid into Arachidonic acid (HY-109590) in hepatoma cells, the activation of prostaglandin H synthase and thromboxane synthesis in isolated platelets. 6,9,12,15,18-Heneicosapentaenoic acid is weak inducer of acyl-CoA oxidase in hepatoma cells.
    6,9,12,15,18-Heneicosapentaenoic acid
  • HY-141612
    Pyrrolidino PAF C-16 91021-63-5 98%
    Pyrrolidino PAF C-16 is a platelet activating factor ( PAF ) analogue that has hypohematic effects.
    Pyrrolidino PAF C-16
  • HY-14182S
    Vernakalant-d6 hydrochloride 866455-16-5 98%
    Vernakalant-d6 (hydrochloride) is deuterium labeled Vernakalant.
    Vernakalant-d6 hydrochloride
  • HY-142019
    Tanshinol borneol ester 1623012-10-1 98%
    Tanshinol borneol ester, an angiogenesis stimulator, promoted multiple key steps of angiogenesis through Akt and MAPK signalling pathways. Tanshinol borneol ester has anti-ischemic and anti-atherosclerosis activities.
    Tanshinol borneol ester
  • HY-142050
    (R)-IDHP 950665-05-1 98%
    (R)-IDHP is an isomer of IDHP, a salvia metabolite that exerts vasorelaxant effects by inhibiting Ca2+ release and Ca2+ inward flow in voltage-dependent and receptor-operated calcium channels in vascular smooth muscle cells. IDHP is used in studies of cardiovascular disease.
    (R)-IDHP
  • HY-14252A
    Milrinone lactate 100286-97-3 98%
    Milrinone lactate is a potent inotropic dilating agent. Milrinone lactate shows simultaneous positive inotropic and vasodilating activities. Milrinone lactate promotes reduction of SVR and PVR in patients with DCM and NYHA class III and IV of heart failure. Milrinone lactate has the potential for the research of cardiovascular function after cardiac surgery and in septic shock.
    Milrinone lactate
  • HY-14252S
    Milrinone-d3 2749393-50-6 98%
    Milrinone-d3 is deuterium labeled Milrinone. Milrinone is a PDE3 inhibitor, and also an inotrope and vasodilator.
    Milrinone-d3
  • HY-142620
    TRPV4 antagonist 3 2681273-35-6 98%
    TRPV4 antagonist 3 is a TRPV4 antagonist (pIC50 = 8.4).
    TRPV4 antagonist 3
  • HY-142691
    DCN1-UBC12-IN-1 2374827-31-1 98%
    DCN1-UBC12-IN-1 is potent and selective DCN1-UBC12 inhibitor with an IC50 of 2.86 nM. Anticardiac fibrotic effect.
    DCN1-UBC12-IN-1
  • HY-142692
    DCN1-UBC12-IN-3 2374827-45-7 98%
    DCN1-UBC12-IN-3 is potent and selective DCN1-UBC12 inhibitor with an IC50 of 2.25 nM. Anticardiac fibrotic effect.
    DCN1-UBC12-IN-3
  • HY-142694
    DCN1-UBC12-IN-2 2374827-47-9 98%
    DCN1-UBC12-IN-2 is a potent and specific DCN1-UBC12 inhibitor (IC50=9.55 nM). DCN1-UBC12-IN-2 could specifically target DCN1-UBC12 interaction and relieve Ang II-induced cardiac fibroblast activation.
    DCN1-UBC12-IN-2
  • HY-142697
    SGC agonist 1 1426309-31-0 98%
    SGC agonist 1 is a potent agonist of soluble guanylate cyclase (SGC). SGC agonist 1 improves solubility combined with high cell permeability. SGC agonist 1 has the potential for the research of cardiovascular disease (extracted from patent WO2016030354A1, compound 18A).
    SGC agonist 1
  • HY-142698
    SGC agonist 2 2735713-77-4 98%
    SGC agonist 2 is a potent agonist of soluble guanylate cyclase (SGC). Soluble guanylate cyclase is a key signal transduction enzyme in the NO-sGC-cGMP signaling pathway. SGC agonist 2 has the potential for the research of cardiovascular disease (heart failure, pulmonary hypertension, angina, myocardial infarction) and fibrotic diseases (renal fibrosis, systemic sclerosis) (extracted from patent WO2021219088A1, compound 031).
    SGC agonist 2
  • HY-14284S
    Nilvadipine-d4 98%
    Nilvadipine-d4 is deuterium labeled Nilvadipine. Nilvadipine is a potent calcium channel antagonist, and the IC50 value is around 0.1 nM.
    Nilvadipine-d4
  • HY-142972
    19(S)-HETE 115461-40-0 98%
    19(S)-HETE is an arachidonic acid metabolite produced by cytochrome P450 enzymes. 19(S)-HETE is a full orthosteric agonist of the prostacyclin (IP) receptor with an EC50 value of 567 nM. 19(S)-HETE inhibits platelet activation and relaxation of vessels.
    19(S)-HETE
  • HY-14299D
    Indacaterol acetate 1000160-96-2 98%
    Indacaterol acetate is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol acetate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol acetate can also be used in cardiovascular disease research.
    Indacaterol acetate
Cat. No. Product Name / Synonyms Application Reactivity